Blog

Abstract from Lancet Oncology regarding Neoadjuvant chemotherapy in Early Breast Cancer

A meta analysis of Ten randomized control trials on the role of neoadjuvant chemotherapy in early breast cancer was reported in Lancet Oncology by Early Breast Cancer Trialist Collaborative  Group

It concludes ” Tumours downsized by NACT might have higher local recurrence after breast-conserving therapy than might tumours of the same dimensions in women who have not received NACT. Strategies to mitigate the increased local recurrence after breast-conserving therapy in tumours downsized by NACT should be considered—eg, careful tumour localisation, detailed pathological assessment, and appropriate radiotherapy.”

Please find the link to the article here

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30777-5/abstract

 

 

Advertisements

Brahma’s Life Span

Brahma’s life span is 100 years. Each year consists of 360 days. However, each day of Brahma’s life is equivalent to 432x 10 7  earth years. A similar number of years constitutes each night.  At the end of one day all of creation has ended and next day creation happens all over again.

                Each day is divided into 14 Manvantarams , each being under one Manu. Every Manvantaram is divided into 71 Maha Yugams. So, in effect, 14 Manvantarams have 14×71=994 Maha Yugams. Six Maha yugams is the period between two Manvantarams.  This set of 1000 Mahayugams is called a Kalpam  and that is a day in Brahma’s life.

                Each Maha Yuga is composed of 4 Yugas.

Kruta Yuga-17,28,000 years

Treta Yuga-12,96,000 years

Dwapara Yuga-8,64,000 years

Kali Yuga-4,32,000 years

So-43,20,000 years is one Maha Yuga

Bhagavad Gita

तेषां ज्ञानी नित्ययुक्त एकभक्तिर्विशिष्यते |

प्रियो हि ज्ञानिनोsत्यर्थमहं स च मम प्रियः ||

Chapter 7 Verse 17

Of these, the wise man, ever steadfast and devoted to the One, excels; for , supremely dear am I to the wise and he is dear to me.

 

 

DESKTOP III Trial -ASCO 2017 Abstract

Results of DESKTOP III ( Progression Free Survival) have been published recently in ASCO Abstracts

The median Progression free survival in patients undergoing secondary cytoreduction for relapsed ovarian cancer (with 6 months plus platinum free interval, positive AGO score ie., ECOG 0,<500 mL Ascites, complete resection at first surgery) was 19.6 months versus 14 months without surgery.

The abstract can be accessed here

http://abstracts.asco.org/199/AbstView_199_187518.html

 

Bhagavad Gita

यो न ह्रुष्यति न द्वेष्टि न शोचाति न काङ्क्षति |

शुभाशुभपरित्यागी भक्तिमान्यः स मे प्रियः ||

Chapter 12 Verse 17

He who neither rejoices nor hates nor grieves nor sesires, renouncing good and evil,full of devotion, he is dear to me.

Bhagavad Gita

कर्मण्यकर्म यः पश्येदकर्मणि च यः|

स बुद्धिमान्मनुष्येषु स युक्तः कृत्स्नकर्मक्र्त ||

He who sees inaction in action, and action in inaction, he is wise among men, he is a yogi and accomplisher of everything

Chapter 4 verse 18